Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Kratom Policy topic
No spam. Unsubscribe anytime.
Kratom ban ("Matthew Davenport" law) advances after hours of emotional testimony and sharp divide
Summary
After extended testimony from law‑enforcement officials, medical experts, users and small‑business owners, the panel voted to send HB 16‑49 — a proposed ban on kratom and certain derivatives — to full judiciary; supporters cited overdose deaths and enforcement gaps, opponents urged regulation rather than prohibition.
The House Criminal Justice Subcommittee voted to send House Bill 16‑49, commonly referred to in testimony as the Matthew Davenport law, to the full Judiciary Committee after several hours of testimony for and against the measure.
Sponsor testimony described six core provisions: prohibiting sale and distribution of kratom and specified alkaloids, criminal penalties for violations, strengthened toxicology testing in suspected overdose deaths and in neonatal abstinence cases, workplace‑drug policy updates through rulemaking, and designating the act effective July 1, 2026. After the sponsor's opening, the committee heard immediate law‑enforcement support from Steven Crump (Tennessee District Attorney General Conference), Mark Delaney (Special Agent in Charge, TBI Dangerous Drugs Task Force), and Tommy Farmer (TBI Dangerous Drugs Task Force). Crump and Delaney warned of rising reports of abuse, chemical analogs (7‑OH and other synthetic derivatives), and laboratory challenges distinguishing natural kratom from synthetic products; Delaney said synthetic products have produced more potent, dangerous exposures.
"Kratom contains an active compound called metragenine and 7‑hydroxy metragenine," a law‑enforcement witness said, citing concerns about chemically altered products and increased reports of addiction and overdose. The sponsor and witnesses urged statutory clarity to allow prosecution and to require expanded toxicology to improve surveillance.
Opposing testimony came from industry and consumers who urged regulation rather than a ban. Walker Gollman of the Global Kratom Coalition argued that natural leaf kratom has a long history of use and that the federal approach is targeting concentrated synthetic 7‑OH products rather than natural leaf. Business owners and patrons from kava/kratom venues — including Walker Gollman, Ryan Holding (Passage Kava Lounge), Jennifer Gillis and others — said a complete ban would criminalize responsible users and close small businesses that test products and maintain age limits.
Medical and recovery professionals gave mixed testimony. Dr. Matthew Bruin and Dr. Nicholas Conley described patients entering treatment with kratom‑related dependence and withdrawal patterns requiring specialized protocols; they said primary‑kratom cases in treatment have risen. By contrast, witnesses including Warren Holding cited Tennessee Department of Health briefings showing a small number of deaths with only kratom present in toxicology, and urged data‑driven policy.
Karen Davenport, mother of Matthew Davenport, delivered an emotional statement describing her son's death on March 18, 2024, which she said resulted from a lethal interaction between prescribed medications and an unregulated kratom product. "He believed the lie that natural was safe," she said, urging lawmakers to pass the bill to prevent further tragedies.
After the testimony period, the committee called the previous question and voted to send HB 16‑49 to full judiciary (8 ayes, 0 nos, 1 present not voting). Committee members flagged the need for clearer testing standards and enforcement paths as the bill proceeds.
This article reports testimony and the committee vote; the bill's statutory language and its fiscal or enforcement details will be examined in more detail in the full Judiciary Committee.
